Q2 2026 Cytokinetics Inc Earnings Call Transcript

Aug 6, 2026 / 08:30 PM GMT

Release Date Price: €71.28

Transcript 10-Q8-K

Key Points

Positve

Cytokinetics Inc (CYTK) reported strong commercial momentum for Mycorzo in the US, with Q2 dispensed patients nearly tripling to 1,500 and new-to-brand prescription share exceeding 40% by quarter end.
The company successfully launched Mycorzo in Germany, its first European market, and received marketing authorization and reimbursement guidance in the UK, expanding its global footprint.
Positive top-line results from the Acacia-HCM Phase 3 trial in non-obstructive HCM met both dual primary endpoints, supporting a potential label expansion and a planned sNDA submission in Q4 2026.
Physician awareness and engagement are rising, with unaided awareness among high-volume prescribers increasing to 68% and over 2,500 healthcare providers completing REMS certification since launch.
The company fortified its balance sheet with a public offering generating approximately $760 million in net proceeds, ending Q2 with about $1.7 billion in cash and investments.
Pipeline progress continues with enrollment advancing in the confirmatory Phase 3 COMET-HF trial for omecamtiv mecarbil and the Phase 1 AMBER-HF study for aficamten, alongside a planned presentation of full Acacia-HCM data at ESC.

Negative

Cytokinetics Inc (CYTK) reported a net loss of $198.8 million for Q2 2026, wider than the $134.4 million loss in the same period of 2025, driven by increased SG&A expenses.
The company raised its full-year 2026 GAAP combined R&D and SG&A expense guidance to $860-$890 million, up from the prior range, reflecting higher commercial readiness investments.
Product revenue of $25.3 million remains modest relative to operating expenses, with US net product revenues of $23 million and European contributions of only $2.3 million.
The launch is still early, with only about 700 unique US prescribers and an average of 3 patients per prescriber, indicating limited depth of prescribing among the broader physician base.
A significant gap exists between prescriptions written (approximately 2,000 in Q2) and dispensed (1,500), with a lengthy process involving REMS enrollment, benefit investigation, and prior authorization potentially delaying revenue recognition.
The company faces uncertainty regarding regulatory approval for the NHCM indication, with no guarantee of priority review or successful sNDA submission, and potential label distinctions between OHCM and NHCM remain unclear.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CYTK.OQ - Cytokinetics, Incorporated
Q2 2026 Cytokinetics Inc Earnings Call
Aug 06, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to the Cytokinetics Q2 2026 earnings conference call.

This call is being recorded and all participants are in a listen-only mode.

After the speaker's remarks, we will open the call to questions.

We will allow for one question per participant.

If you would like to ask a question this time.

Simply press star, followed by the number 1 on your telephone keypad.

Question, press star 1 again.

I would now like to turn the call over to Diane Weiser, cytokinetics senior Vice President of Diane, please go ahead.

Good afternoon and thanks for joining us.

The slides accompanying today's webcast can be found on the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.